ACTELION PHARMACEUTICALS, a Janssen Pharmaceutical Company of Johnson and Johnson, GRANT PORTAL
Pulmonary Hypertension: Pulmonary Hypertension focuses on the discovery, development and commercialization of innovative treatments to serve critical, unmet medical needs. We strive on delivering ground-breaking medicines that improve patients' lives. We offer funding and support because we believe organizations are an important support network and source for raising awareness and providing education.

No live programming will be supported for the remainder of 2020 and into 2021. Virtual programs ONLY. Live programming will be considered once the pandemic restrictions are lifted in full.

Please click here to complete a Janssen required Certificate of Separation. This document must be completed, signed, and uploaded to your organization profile to complete the CME review process.

***As of October 15, 2020, CHARITABLE CONTRIBUTION APPLICATIONS ARE NO LONGER ACCEPTED THROUGH THIS PORTAL*** Please click here to request a Charitable Contribution applications. Thank you.

This portal no longer accepts SPONSORSHIP APPLICATIONS. Please contact Dana Roman at droman10@its.jnj.com regarding all Sponsorship Applications Thank you.

Areas Of Interest: What are Pulmonary Hypertension US Educational Objectives?

  • Increase awareness of Pulmonary Arterial Hypertension (PAH) and associated diseases.
  • Increase awareness of the need for early recognition, diagnosis, and treatment of PAH.
  • Expand knowledge basis for the appropriate use of currently available PAH therapies.
  • Explore emerging science as it relates to improved diagnosis and treatment of PAH.

What therapeutic areas will be considered by Pulmonary Hypertension?

    Pulmonary Hypertension supports legitimate, independent, bona fide educational programs related to PAH and other therapeutic areas and disease states consistent with the medical and research objectives developed by Pulmonary Hypertension's Medical Affairs Department.

Actelion requires that all grants are submitted at least 60 days in advance of the venue start date.

Please be aware that seeking multi-support is required in order to be eligible for consideration.

    Does your request fall within the guidelines listed above?